Keep an eye on this stock: Veru Inc. (NASDAQ: VERU), the constant rise in the late hours
Veru Inc. (NASDAQ: VERU), the stock kept on staying up 16.35% to $11.28 in after-market as the biotech oncology company focusing on the development of novel prostate and breast cancer management medicines, unveils positive Phase 2 clinical trial results for the selected oral, novel selective androgen receptor (AR) targeting agent enobosarm for the treatment of […]
Keep an eye on why Veru Inc. (NASDAQ: VERU) are shares soaring above limits in the premarket?
Veru Inc. (NASDAQ: VERU), the stock jumped 21.79% to $7.74 in the premarket session after a biopharmaceutical oncology corporation focused on the production of new cancer treatment drugs, today reported high net sales and gross profit for its fourth quarter and full-year ended September 30, 2020, for fiscal 2020. 4th-quarter: YOY highlights From $8.7 million, […]
